Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is an attractive investment opportunity due to their strong pipeline of clinical-stage product candidates, which have shown positive results in recent trials. Their targeted approach to oncology treatments, integrating small molecule drug discovery with biomarker identification, indicates a high potential for success in developing precision medicine for select patient populations. With multiple successful trials and an expanding pipeline, the company is poised for growth and has a promising outlook for the future.

Bears say

IDEAYA Biosciences is a precision medicine oncology company with a focus on synthetic lethality. However, their limited details on safety and tolerability for their clinical-stage product candidates, combined with previously reported high rates of Grade 3+ TEAEs and TRAE discontinuations, raise concerns about the potential challenges in the development of their core assets. Additionally, their valuation of $54/share is based on optimistic assumptions, which may not be achievable given these potential issues.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.